Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: Impact of APOE4 genotype

Neurobiology of Aging

Volumn 36, Issue 10, 2015, Pages 2687-2701

  Gispert, J D ^a,b   Rami, L ^c,d   Sanchez Benavides G ^e   Falcon, C ^a,b   Tucholka, A ^a   Rojas, S ^a,f   Molinuevo, J L ^a,c,d  

^a Barcelonaßeta Brain Research Center   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Amyloid; Biomarkers; Brain; MRI; Neuroinflammation; Tau; VBM

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PROTEIN; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; APOE4 GENE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC ASSOCIATION; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; INFERIOR PARIETAL CORTEX; INSULA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; SUPRAMARGINAL GYRUS; TEMPORAL CORTEX; ALLELE; ATROPHY; CEREBROSPINAL FLUID; GENETICS; GENOTYPE; HETEROZYGOTE; MIDDLE AGED; NEUROIMAGING; PARIETAL LOBE; PATHOLOGY; TEMPORAL LOBE;

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ATROPHY; DISEASE PROGRESSION; FEMALE; GENOTYPE; GRAY MATTER; HETEROZYGOTE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; PARIETAL LOBE; TAU PROTEINS; TEMPORAL LOBE;

EID: 84940958973     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.06.027     Document Type: Article

References (86)

1. Alemán-Gómez, Y., Melie-García, L., Valdés-Hernandez, P., 2006. IBASPM: toolbox for automatic parcellation of brain structures. 12th Annual Meeting of the Organization for Human Brain Mapping, Florence, Italy.
2. Apostolova L.G., Hwang K.S., Andrawis J.P., Green A.E., Babakchanian S., Morra J.H., Cummings J.L., Toga A.W., Trojanowski J.Q., Shaw L.M., Jack C.R., Petersen R.C., Aisen P.S., Jagust W.J., Koeppe R.A., Mathis C.A., Weiner M.W., Thompson P.M. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol. Aging 2010, 31:1284-1303.
3. Basso M., Gelernter J., Yang J., MacAvoy M.G., Varma P., Bronen R.A., van Dyck C.H. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiol. Aging 2006, 27:1416-1424.
4. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367:795-804.
5. Becker J.A., Hedden T., Carmasin J., Maye J., Rentz D.M., Putcha D., Fischl B., Greve D.N., Marshall G.A., Salloway S., Marks D., Buckner R.L., Sperling R.A., Johnson K.A. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann. Neurol. 2011, 69:1032-1042.
6. Beckett L.A., Harvey D.J., Gamst A., Donohue M., Kornak J., Zhang H., Kuo J.H. The Alzheimer's disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010, 6:257-264.
7. Bookheimer S., Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu. Rev. Clin. Psychol. 2009, 5:343-362.
8. Bourgeat P., Chetelat G., Villemagne V.L., Fripp J., Raniga P., Pike K., Acosta O., Szoeke C., Ourselin S., Ames D., Ellis K.A., Martins R.N., Masters C.L., Rowe C.C., Salvado O. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74:121-127.
9. Braak H., Zetterberg H., Del Tredici K., Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013, 126:631-641.
10. Brown J.A., Terashima K.H., Burggren A.C., Ercoli L.M., Miller K.J., Small G.W., Bookheimer S.Y. Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:20760-20765.
11. Burggren A.C., Zeineh M.M., Ekstrom A.D., Braskie M.N., Thompson P.M., Small G.W., Bookheimer S.Y. Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage 2008, 41:1177-1183.
12. Carter S.F., Scholl M., Almkvist O., Wall A., Engler H., Langstrom B., Nordberg A. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 2012, 53:37-46.
13. Chetelat G., La Joie R., Villain N., Perrotin A., de La Sayette V., Eustache F., Vandenberghe R. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013, 2:356-365.
14. Chetelat G., Villemagne V.L., Bourgeat P., Pike K.E., Jones G., Ames D., Ellis K.A., Szoeke C., Martins R.N., O'Keefe G.J., Salvado O., Masters C.L., Rowe C.C. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann. Neurol. 2010, 67:317-324.
15. Chetelat G., Villemagne V.L., Pike K.E., Baron J.C., Bourgeat P., Jones G., Faux N.G., Ellis K.A., Salvado O., Szoeke C., Martins R.N., Ames D., Masters C., Rowe C.C. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010, 133:3349-3358.
16. Choo I.L., Carter S.F., Scholl M.L., Nordberg A. Astrocytosis measured by (1)(1)C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur. J. Nucl. Med. Mol. Imaging 2014, 41:2120-2126.
17. Cuadra M.B., Cammoun L., Butz T., Cuisenaire O., Thiran J.P. Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images. IEEE Trans. Med. Imaging 2005, 24:1548-1565.
18. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., Rusinek H., Li J., Tsui W., Saint Louis L.A., Clark C.M., Tarshish C., Li Y., Lair L., Javier E., Rich K., Lesbre P., Mosconi L., Reisberg B., Sadowski M., DeBernadis J.F., Kerkman D.J., Hampel H., Wahlund L.O., Davies P. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 2006, 27:394-401.
19. de Souza L.C., Chupin M., Lamari F., Jardel C., Leclercq D., Colliot O., Lehericy S., Dubois B., Sarazin M. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol. Aging 2012, 33:1253-1257.
20. den Heijer T., Oudkerk M., Launer L.J., van Duijn C.M., Hofman A., Breteler M.M. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 2002, 59:746-748.
21. Desikan R.S., McEvoy L.K., Holland D., Thompson W.K., Brewer J.B., Aisen P.S., Andreassen O.A., Hyman B.T., Sperling R.A., Dale A.M. Apolipoprotein E epsilon4 does not modulate amyloid-beta-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am. J. Neuroradiol. 2013, 34:505-510.
22. Desikan R.S., McEvoy L.K., Thompson W.K., Holland D., Roddey J.C., Blennow K., Aisen P.S., Brewer J.B., Hyman B.T., Dale A.M. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann. Neurol. 2011, 70:657-661.
23. Dickerson B.C., Bakkour A., Salat D.H., Feczko E., Pacheco J., Greve D.N., Grodstein F., Wright C.I., Blacker D., Rosas H.D., Sperling R.A., Atri A., Growdon J.H., Hyman B.T., Morris J.C., Fischl B., Buckner R.L. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 2009, 19:497-510.
24. Donix M., Burggren A.C., Scharf M., Marschner K., Suthana N.A., Siddarth P., Krupa A.K., Jones M., Martin-Harris L., Ercoli L.M., Miller K.J., Werner A., von Kummer R., Sauer C., Small G.W., Holthoff V.A., Bookheimer S.Y. APOE associated hemispheric asymmetry of entorhinal cortical thickness in aging and Alzheimer's disease. Psychiatry Res. 2013, 214:212-220.
25. Donix M., Burggren A.C., Suthana N.A., Siddarth P., Ekstrom A.D., Krupa A.K., Jones M., Rao A., Martin-Harris L., Ercoli L.M., Miller K.J., Small G.W., Bookheimer S.Y. Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. Neuroimage 2010, 53:37-43.
26. Dore V., Villemagne V.L., Bourgeat P., Fripp J., Acosta O., Chetelat G., Zhou L., Martins R., Ellis K.A., Masters C.L., Ames D., Salvado O., Rowe C.C. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013, 70:903-911.
27. Drago V., Babiloni C., Bartres-Faz D., Caroli A., Bosch B., Hensch T., Didic M., Klafki H.W., Pievani M., Jovicich J., Venturi L., Spitzer P., Vecchio F., Schoenknecht P., Wiltfang J., Redolfi A., Forloni G., Blin O., Irving E., Davis C., Hardemark H.G., Frisoni G.B. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J. Alzheimers Dis. 2011, 26(Suppl 3):159-199.
28. Driscoll I., Zhou Y., An Y., Sojkova J., Davatzikos C., Kraut M.A., Ye W., Ferrucci L., Mathis C.A., Klunk W.E., Wong D.F., Resnick S.M. Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol. Aging 2011, 32:2123-2130.
29. Espeseth T., Westlye L.T., Fjell A.M., Walhovd K.B., Rootwelt H., Reinvang I. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol. Aging 2008, 29:329-340.
30. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 2009, 65:176-183.
31. Fan M., Liu B., Zhou Y., Zhen X., Xu C., Jiang T. Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults. Neurosci. Lett. 2010, 479:332-336.
32. Fennema-Notestine C., Panizzon M.S., Thompson W.R., Chen C.H., Eyler L.T., Fischl B., Franz C.E., Grant M.D., Jak A.J., Jernigan T.L., Lyons M.J., Neale M.C., Seidman L.J., Tsuang M.T., Xian H., Dale A.M., Kremen W.S. Presence of ApoE epsilon4 allele associated with thinner frontal cortex in middle age. J. Alzheimers Dis. 2011, 26(Suppl 3):49-60.
33. Fjell A.M., McEvoy L., Holland D., Dale A.M., Walhovd K.B. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog. Neurobiol. 2014, 117:20-40.
34. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Blennow K., Brewer J.B., Dale A.M. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb. Cortex 2010, 20:2069-2079.
35. Fleisher A., Grundman M., Jack C.R., Petersen R.C., Taylor C., Kim H.T., Schiller D.H., Bagwell V., Sencakova D., Weiner M.F., DeCarli C., DeKosky S.T., van Dyck C.H., Thal L.J. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch. Neurol. 2005, 62:953-957.
36. Fortea J., Sala-Llonch R., Bartres-Faz D., Llado A., Sole-Padulles C., Bosch B., Antonell A., Olives J., Sanchez-Valle R., Molinuevo J.L., Rami L. Cognitively preserved subjects with transitional cerebrospinal fluid beta-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biol. Psychiatry 2011, 70:183-190.
37. Fortea J., Vilaplana E., Alcolea D., Carmona-Iragui M., Sanchez-Saudinos M.B., Sala I., Anton-Aguirre S., Gonzalez S., Medrano S., Pegueroles J., Morenas E., Clarimon J., Blesa R., Lleo A. Cerebrospinal fluid beta-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann. Neurol. 2014, 76:223-230.
38. Fotenos A.F., Mintun M.A., Snyder A.Z., Morris J.C., Buckner R.L. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch. Neurol. 2008, 65:113-120.
39. Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:67-77.
40. Glodzik-Sobanska L., Pirraglia E., Brys M., de Santi S., Mosconi L., Rich K.E., Switalski R., Saint Louis L., Sadowski M.J., Martiniuk F., Mehta P., Pratico D., Zinkowski R.P., Blennow K., de Leon M.J. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol. Aging 2009, 30:672-681.
41. Hampel H., Burger K., Pruessner J.C., Zinkowski R., DeBernardis J., Kerkman D., Leinsinger G., Evans A.C., Davies P., Moller H.J., Teipel S.J. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol. 2005, 62:770-773.
42. Hayasaka S., Nichols T.E. Validating cluster size inference: random field and permutation methods. Neuroimage 2003, 20:2343-2356.
43. Henneman W.J., Vrenken H., Barnes J., Sluimer I.C., Verwey N.A., Blankenstein M.A., Klein M., Fox N.C., Scheltens P., Barkhof F., van der Flier W.M. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009, 73:935-940.
44. Hill D.L., Schwarz A.J., Isaac M., Pani L., Vamvakas S., Hemmings R., Carrillo M.C., Yu P., Sun J., Beckett L., Boccardi M., Brewer J., Brumfield M., Cantillon M., Cole P.E., Fox N., Frisoni G.B., Jack C., Kelleher T., Luo F., Novak G., Maguire P., Meibach R., Patterson P., Bain L., Sampaio C., Raunig D., Soares H., Suhy J., Wang H., Wolz R., Stephenson D. Coalition against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimers Dement. 2014, 10:421-429.
45. Hyman B.T. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 2011, 8:1062-1064.
46. Insel P.S., Mattsson N., Donohue M.C., Mackin R.S., Aisen P.S., Jack C.R., Shaw L.M., Trojanowski J.Q., Weiner M.W. The transitional association between beta-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2014.
47. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
48. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
49. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131(Pt 3):665-680.
50. Jack C.R., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Lowe V., Kantarci K., Bernstein M.A., Senjem M.L., Gunter J.L., Boeve B.F., Trojanowski J.Q., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Knopman D.S. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch. Neurol. 2012, 69:856-867.
51. Johnson K.A., Fox N.C., Sperling R.A., Klunk W.E. Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006213.
52. Julkunen V., Niskanen E., Koikkalainen J., Herukka S.K., Pihlajamaki M., Hallikainen M., Kivipelto M., Muehlboeck S., Evans A.C., Vanninen R., Hilkka S. Differences in cortical thickness in healthy controls, subjects with mild cognitive impairment, and Alzheimer's disease patients: a longitudinal study. J. Alzheimers Dis. 2010, 21:1141-1151.
53. Kreisl W.C., Lyoo C.H., McGwier M., Snow J., Jenko K.J., Kimura N., Corona W., Morse C.L., Zoghbi S.S., Pike V.W., McMahon F.J., Turner R.S., Innis R.B. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 2013, 136:2228-2238.
54. Lemaitre H., Crivello F., Dufouil C., Grassiot B., Tzourio C., Alperovitch A., Mazoyer B. No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage 2005, 24:1205-1213.
55. Liu Y., Paajanen T., Westman E., Wahlund L.O., Simmons A., Tunnard C., Sobow T., Proitsi P., Powell J., Mecocci P., Tsolaki M., Vellas B., Muehlboeck S., Evans A., Spenger C., Lovestone S., Soininen H. Effect of APOE epsilon4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J. Alzheimers Dis. 2010, 21:947-966.
56. Manjon J.V., Coupe P., Marti-Bonmati L., Collins D.L., Robles M. Adaptive non-local means denoising of MR images with spatially varying noise levels. J. Magn. Reson. Imaging 2010, 31:192-203.
57. Manning E.N., Barnes J., Cash D.M., Bartlett J.W., Leung K.K., Ourselin S., Fox N.C. APOE epsilon4 is associated with disproportionate progressive hippocampal atrophy in AD. PLoS One 2014, 9:e97608.
58. Mattsson N., Insel P., Nosheny R., Trojanowski J.Q., Shaw L.M., Jack C.R., Tosun D., Weiner M. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol. Aging 2014, 35:614-622.
59. Mattsson N., Insel P.S., Nosheny R., Tosun D., Trojanowski J.Q., Shaw L.M., Jack C.R., Donohue M.C., Weiner M.W. Emerging beta-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 2014, 71:725-734.
60. Molinuevo J.L., Gispert J.D., Dubois B., Heneka M.T., Lleo A., Engelborghs S., Pujol J., de Souza L.C., Alcolea D., Jessen F., Sarazin M., Lamari F., Balasa M., Antonell A., Rami L. The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. J. Alzheimers Dis. 2013, 36:67-77.
61. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132(Pt 5):1310-1323.
62. Potkin S.G., Guffanti G., Lakatos A., Turner J.A., Kruggel F., Fallon J.H., Saykin A.J., Orro A., Lupoli S., Salvi E., Weiner M., Macciardi F. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One 2009, 4:e6501.
63. Protas H.D., Chen K., Langbaum J.B., Fleisher A.S., Alexander G.E., Lee W., Bandy D., de Leon M.J., Mosconi L., Buckley S., Truran-Sacrey D., Schuff N., Weiner M.W., Caselli R.J., Reiman E.M. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 2013, 70:320-325.
64. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 334:752-758.
65. Reiman E.M., Uecker A., Caselli R.J., Lewis S., Bandy D., de Leon M.J., De Santi S., Convit A., Osborne D., Weaver A., Thibodeau S.N. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann. Neurol. 1998, 44:288-291.
66. Sabuncu M.R., Desikan R.S., Sepulcre J., Yeo B.T., Liu H., Schmansky N.J., Reuter M., Weiner M.W., Buckner R.L., Sperling R.A., Fischl B. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch. Neurol. 2011, 68:1040-1048.
67. Schott J.M., Bartlett J.W., Fox N.C., Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann. Neurol. 2010, 68:825-834.
68. Schuff N., Tosun D., Insel P.S., Chiang G.C., Truran D., Aisen P.S., Jack C.R., Weiner M.W. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol. Aging 2012, 33:845-855.
69. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132(Pt 4):1067-1077.
70. Shaw P., Lerch J.P., Pruessner J.C., Taylor K.N., Rose A.B., Greenstein D., Clasen L., Evans A., Rapoport J.L., Giedd J.N. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007, 6:494-500.
71. Shi J., Lepore N., Gutman B.A., Thompson P.M., Baxter L.C., Caselli R.J., Wang Y. Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: an N = 725 surface-based Alzheimer's disease neuroimaging initiative study. Hum. Brain Mapp. 2014, 35:3903-3918.
72. Sluimer J.D., Vrenken H., Blankenstein M.A., Fox N.C., Scheltens P., Barkhof F., van der Flier W.M. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 2008, 70(19 Pt 2):1836-1841.
73. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L., Mazziotta J.C., Saxena S., Wu H.M., Mega M.S., Cummings J.L., Saunders A.M., Pericak-Vance M.A., Roses A.D., Barrio J.R., Phelps M.E. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6037-6042.
74. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 2009, 66:1476-1481.
75. Stricker N.H., Dodge H.H., Dowling N.M., Han S.D., Erosheva E.A., Jagust W.J. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav. 2012, 6:599-609.
76. Struyfs H., Molinuevo J.L., Martin J.J., De Deyn P.P., Engelborghs S. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. J. Alzheimers Dis. 2014, 41:903-909.
77. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., Csako G., Levy J.A., Bartko J.J., Cohen R.M. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol. Psychiatry 2004, 56:670-676.
78. Teipel S.J., Peters O., Heuser I., Jessen F., Maier W., Froelich L., Arlt S., Hull M., Gertz H.J., Kornhuber J., Wiltfang J., Thome J., Rienhoff O., Meindl T., Hampel H., Grothe M. Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: effect of different processing and analysis approaches on sample sizes. World J. Biol. Psychiatry 2011, 12(Suppl 1):109-113.
79. Tosun D., Schuff N., Shaw L.M., Trojanowski J.Q., Weiner M.W. Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. J. Alzheimers Dis. 2011, 26(Suppl 3):77-90.
80. Tosun D., Schuff N., Truran-Sacrey D., Shaw L.M., Trojanowski J.Q., Aisen P., Peterson R., Weiner M.W. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol. Aging 2010, 31:1340-1354.
81. Trachtenberg A.J., Filippini N., Ebmeier K.P., Smith S.M., Karpe F., Mackay C.E. The effects of APOE on the functional architecture of the resting brain. Neuroimage 2012, 59:565-572.
82. Trachtenberg A.J., Filippini N., Mackay C.E. The effects of APOE-epsilon4 on the BOLD response. Neurobiol. Aging 2012, 33:323-334.
83. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
84. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293.
85. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
86. Wolk D.A., Dickerson B.C. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10256-10261.